Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 September 2006, Vol. 108, No. 5, pp. 1569-1570.
Prepublished online as a Blood First Edition Paper on April 27, 2006; DOI 10.1182/blood-2006-03-009548.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-03-009548v1
108/5/1569    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mazzolai, L.
Right arrow Articles by Duchosal, M. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mazzolai, L.
Right arrow Articles by Duchosal, M. A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted March 13, 2006
Accepted April 18, 2006

Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy

Lucia Mazzolai*, Patrick Hohlfeld, Francois Spertini, Daniel Hayoz, Marc Schapira, and Michel A Duchosal

Vascular Medicine, University Hospital of Lausanne (CHUV), Switzerland
Obstetrics, University Hospital of Lausanne (CHUV), Switzerland
Immunology and Allergy, University Hospital of Lausanne (CHUV), Switzerland
Hematology of the University Hospital of Lausanne (CHUV), Switzerland

* Corresponding author; email: lucia.mazzolai{at}chuv.ch.

Heparin is the drug of choice for the treatment or the prevention of thromboembolic disease during pregnancy. However, treatment options are limited when heparin cannot be used because of hypersensitivity skin reactions. Despite the recent availability of new anticoagulant agents, data relating to their use during pregnancy is lacking. This report describes the successful management with fondaparinux, during 150 days, of a pregnant patient with protein S deficiency and prior DVT who developed heparin and danaparoid hypersensitivity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020